The FDA has granted Priority Review to Alexion's BLA for efzimfotase alfa, a biweekly enzyme replacement therapy for hypophosphatasia.

COVID-19 infection is associated with a lower risk for developing type 1 diabetes (T1D) in individuals younger than 30 years.

For adults with T2D receiving SGLT2is, risk factors for ketoacidosis include high HbA1c, previous ketoacidosis, and recent hypoglycemia.

The SMFM released a special statement to offer a structured, multidisciplinary approach to managing sickle cell disease and vaso-occlusive crises during pregnancy.

A proposed machine learning framework for metabolic dysfunction-associated steatotic liver disease may improve personalized risk prediction.

The FDA has approved Kerendia (finerenone) to reduce UACR, which is expected to slow CKD progression in adults with type 1 diabetes.

All participating U.S. comprehensive cancer centers are experiencing a shortage of at least one anticancer agent, with more than 20 percent of centers currently ...

While exocrine pancreatic insufficiency frequently occurs in patients with type 1 diabetes and negatively impacts glycemic control, the lack of association with gastrointestinal symptoms in this ...

Cultural stigma and sensationalized media narratives regarding GLP-1 RAs contribute to patient drug avoidance and treatment ...